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Paucity and discordance of neutralising antibody responses 
to SARS-CoV-2 VOCs in vaccinated immunodeficient 
patients and health-care workers in the UK
As of June, 2021, the UK population is only partly 
vaccinated against COVID-19, with many people 
having received just one vaccination dose (either 
BNT162b2 [Pfizer–BioNTech]) or ChAdOx1 nCoV-19 
[AZD1222; Oxford–AstraZeneca]). Tracking the spread 
of SARS-CoV-2 Variants of Concern (VOCs) remains 
important for understanding the levels of vaccine-
induced immunity and for identifying the emergence 
of vaccine escape variants. The immune correlates of 
protection to SARS-CoV-2 and COVID-19 established in 
phase 3 clinical trials following two doses of vaccine was 
the titre of neutralising antibodies (NAbs) to SARS-CoV-2 
in study groups, before the VOCs emerged.1 Vaccination 
programmes are leading to promising reductions in 
disease severity and mortality in vaccinated populations. 
However, the combined situation of ongoing transmission 
within communities, including in some vaccine recipients, 
alongside newly arising VOCs, continues to pose a serious 
threat to public health and the efficacy of these vaccines. 
As of Jan 11, 2021, in the UK, the interval between the 
first and second dose of vaccination was extended to 
12 weeks. This extension achieved the aim of maximising 
population coverage by immunising the greatest possible 
number of individuals to prevent disease and hospital 
admissions. Encouragingly, a growing number of studies 
have reported a marked reduction in the number of 
individuals with moderate-to-severe clinical symptoms 
and a substantial decline in the number of hospitalised 
patients with COVID-19 in the UK, underscoring the 
success of this strategy.2,3
Many countries, both in the early and advanced stages 
of their vaccination campaigns, are facing new cases 
of infection with VOCs that have acquired mutations 
facilitating increased transmission and evasion of pre-
existing immunity. These VOCs might cause increased 
morbidity and mortality.4–6 The B.1.1.7 (also known as 
Alpha) VOC has been reported in more than 114 countries, 
the B.1.351 (also known as Beta) VOC in more than 
68 countries, and the P.1 (also known as Gamma) VOC 
in more than 37 countries, and new cases continue to be 
reported worldwide. Additional VOCs, such as B.1.617.2, 
are likely to continue to emerge and threaten our ongoing 
COVID-19 vaccination programmes.
Early reports in 2021, suggest that both single-dose 
and two-dose vaccination regimens are showing gaps 
in protection.7,8 In South Africa, a two-dose regimen of 
the ChAdOx1 nCoV-19 vaccine did not show protection 
against mild-to-moderate COVID-19 after infection with 
the B.1.351 variant.9 Additionally, a report of individuals 
immunised with BNT162b2 in Qatar found that vaccine 
effectiveness was 14·9% lower against the B.1.351 VOC 
than the B.1.1.7 VOC, and indicated a notable number 
of breakthrough infections.10 Similar concerns were 
also noted in a case-cohort study in Israel, which found 
disproportionately high infection rates with B.1.351 in 
fully vaccinated compared with unvaccinated individuals.11 
These findings suggest that, despite aggressive immuni-
sation programmes, the presence of circulating VOCs 
represent a serious concern for the emergence of vaccine 
escape variants that are either more transmissable or 
virulent, or both, than the vaccine strain or are able to 
escape vaccine-induced neutralising antibodies.
Understanding the threshold levels of protective 
immunity against VOCs in specific risk groups and in 
the general population during ongoing transmission is 
important for informing and refocusing immunisation 
strategies. Providing data on the immune correlates of 
protection in clinically vulnerable groups is needed to 
inform the development of effective next-generation, 
variant-resistant vaccines. The UK has more than 
3·5 million people on the Shielded Patient List, which 
comprises those who are clinically extremely vulnerable 
and often prone to persistent infections, including 
patients with cancer and transplant recipients. Shielding 
patients have a greater risk of morbidity and mortality 
than the general population, and those with the inability 
to clear infections, such as immunodeficient patients, 
might themselves amplify new viral variants.12
We did a single-centre, cross-sectional study of 
immunodeficient outpatients and health-care workers 
employed at the same tertiary critical care National 
Health Service (NHS) Trust to understand the spectrum 
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of immunity to the B.1 vaccine strain compared with 
three major VOCs after vaccination with one dose of 
either BNT162b2 or ChAdOx1 nCoV-19. To establish the 
current level of immunity to VOCs in a healthy population, 
we compared NAbs induced by either BNT162b2 or 
ChAdOx1 nCoV-19 in 142 vaccinated health-care workers. 
In addition, we screened 107 outpatients with a range 
of immunodeficiencies for the presence of SARS-CoV-2 
binding antibodies. This group included patients with 
both primary and secondary immunodeficiencies, such 
as common variable immunodeficiency syndrome and 
specific polysaccharide antibody deficiency syndrome. We 
assessed the ability of serum antibodies from vaccinated 
health-care workers and immunodeficient outpatients to 
neutralise the B.1 vaccine strain, as well as the three VOCs, 
B.1.1.7, B.1.351, and P.1. We used a validated SARS-CoV-2 
pseudovirus neutralisation assay standardised against 
WHO reference standards (the National Institute for 
Biological Standards and Control) to calculate NAb titres.13
Our results revealed either undetectable antibodies 
or low NAb titres in immunodeficient outpatients, with 
only four (5%) of 80 showing detectable neutralisation of 
B.1.1.7 and two (3%) showing detectable neutralisation 
of B.1.351 (appendix). Although several vaccinated 
health-care workers without previous SARS-CoV-2 
exposure showed a range of NAb titres, these titres 
were markedly lower than in health-care workers with 
previous SARS-CoV-2 exposure (appendix). Of the 
health-care workers without previous SARS-CoV-2 
exposure, 41 (45%) of 94 had detectable NAbs to B.1, 
35 (37%) of 96 to B.1.1.7, nine (9%) of 94 to B.1.351, and 
nine (10%) of 96 to P.1. By contrast, with the exception 
of four individuals with no detectable neutralising 
antibodies, vaccinated health-care workers with previous 
SARS-CoV-2 exposure had marked NAb responses 
against B.1, with an IQR of 1200–3700 international 
units per mL, or 1900–5900 concentration needed to 
achieve 50% inhibition (IC50). Notably, health-care 
workers with previous SARS-CoV-2 exposure showed 
a significant increase in NAb titres to all four strains, 
including the three VOCs, post-vaccination compared 
with pre-vaccination (all p<0·0001; appendix). This 
observation underscores the importance of vaccination, 
even in populations previously exposed to SARS-CoV-2. 
Additionally, this result supports that a second dose of 
vaccination, in individuals without previous exposure to 
SARS-CoV-2, could similarly boost immunity to greater 
protective levels, such as after both natural infection and 
vaccination.
Furthermore, NAb titres to B.1 were highest in 
vaccinated health-care workers with a history of previous 
SARS-CoV-2 infection, with no significant difference 
between the responses induced by BNT162b2 or 
ChAdOx1 nCoV-19 vaccines (p=0·82; appendix). Notably, 
neutralisation of VOCs harbouring the E484K mutation 
(B.1.351 and P.1) was consistently lower than the 
B.1 vaccine strain in health-care workers with no evidence 
of previous SARS-CoV-2 infection (p<0·0001 for both 
strains; appendix). The key finding was the large spectrum 
of NAb titres, and the overall low titres of NAbs, especially 
to B.1.351 and P.1, in health-care workers vaccinated with 
a single-dose, and particularly in those without previous 
SARS-CoV-2 exposure. Furthermore, with the exception 
of one immunodeficient patient with a history of SARS-
CoV-2 infection, average NAb titres were five-fold lower in 
immunodeficient outpatients than in health-care workers 
(appendix), and far lower than the NAb titres associated 
with protection against viruses circulating early in the 
pandemic in phase 3 clinical trials.
These data not only underscore the risk of clinically 
vulnerable patients to infection with SARS-CoV-2, but 
also the risk of onward transmission of VOCs by individual 
health-care workers with no or low NAbs. Our results 
emphasise the importance of extended surveillance of 
the NAb threshold titres associated with protection from 
infection with circulating VOCs or severe disease caused 
by VOCs. Larger population studies will be needed to 
determine the protective NAb threshold titres across 
representative cohorts of the UK population. These 
analyses will help to identify risk groups for follow-up 
immunisations with current vaccines or variant-specific 
successors. Virus NAb threshold studies will inform 
targeted vaccination in communities with outbreaks, and 
the strategic or targeted use of variant-specific vaccines 
in populations with the highest risk. We suggest that 
these studies also include health-care workers with low 
NAb titres and clinically vulnerable immunodeficient 
outpatients. Understanding the existing levels of 
immunity to the VOCs in the overall population will 
inform containment strategies in communities at risk 
of local VOC outbreaks. Additionally, understanding the 
levels of immunity in both the immunocompromised 
and general populations will facilitate the development 
of public health strategies to contain and prevent novel 
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variants of interest or the emergence of vaccine-resistant 
variants that could threaten COVID-19 immunisation 
programmes.
All authors declare no competing interests. We acknowledge support from the 
NIHR/UKRI grant, COV0170 Humoral Immune Correlates of COVID-19 (HICC; 
based at the Laboratory of Viral Zoonotics, University of Cambridge), the Royal 
Papworth Hospital NHS Trust (RPH; supporting HB), and the EU FETopen Grant 
Virofight (supporting RW and SE). AN is supported by Project OVEL (BBSRC, 
UKRI). We thank the RPH Trust and clinical studies team, health-care workers, 
and outpatients who participated in this study. We also thank members of the 
HICC consortium. AN and DC contributed equally to this work. HB and JLH 
contributed equally to this work.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open 
Access article under the CC BY-NC-ND 4.0 license.
Angalee Nadesalingam, Diego Cantoni, David A Wells, 
Ernest T Aguinam, Matteo Ferrari, Peter Smith, Andrew Chan, 
George Carnell, Luis Ohlendorf, Sebastian Einhauser, 
Charlotte George, Ralf Wagner, Nigel Temperton, 
Javier Castillo-Olivares, Helen Baxendale, 
*Jonathan L Heeney, on behalf of the HICC consortium
jlh66@cam.ac.uk
Laboratory of Viral Zoonotics, University of Cambridge, Cambridge CB3 OES, UK 
(AN, DAW, ETA, MF, PS, AC, GC, LO, CG, JC-O, JLH); Viral Pseudotype Unit, Medway 
School of Pharmacy, University of Kent, Medway, UK (DC, NT); Institute of Clinical 
Microbiology and Hygiene (RW) and Institute of Medical Microbiology and 
Hygiene, University of Regensburg, Regensburg, Germany (SE, RW); Clinical 
Immunology Department, Royal Papworth NHS Foundation Trust, 
Cambridge, UK (HB). 
1 Addetia A, Crawford KHD, Dingens A, et al. Neutralizing antibodies correlate 
with protection from SARS-CoV-2 in humans during a fishery vessel 
outbreak with a high attack rate. J Clin Microbiol 2020; 58: e02107–20.
2 Iacobucci G. Covid-19: infections fell by 65% after first dose of AstraZeneca 
or Pfizer vaccine, data show. BMJ 2021; 373: n1068.
3 Hall VJ, Foulkes S, Saei A, et al. COVID-19 vaccine coverage in health-care 
workers in England and effectiveness of BNT162b2 mRNA vaccine against 
infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021; 
397: 1725–35.
4 Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, 
Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of 
concern 202012/1: matched cohort study. BMJ 2021; 372: n579.
5 Freitas ARR, Beckedorff OA, Cavalcanti LP de G, et al. The emergence of novel 
SARS-CoV-2 variant P.1 in Amazonas (Brazil) was temporally associated with 
a change in the age and gender profile of COVID-19 mortality. SSRN 2021; 
published online April 14. https://papers.ssrn.com/sol3/papers.
cfm?abstract_id=3804788 (preprint).
6 Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K, Keogh RH. 
Increased mortality in community-tested cases of SARS-CoV-2 lineage 
B.1.1.7. Nature 2021; 593: 270–74.
7 Dejnirattisai W, Zhou D, Supasa P, et al. Antibody evasion by the 
P.1 strain of SARS-CoV-2. Cell 2021; 184: 2939–54.e9.
8 Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 
variant B.1.351 from natural and vaccine-induced sera. Cell 2021; 
184: 2348–61.e6.
9 Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 
Covid-19 vaccine against the B.1.351 variant. N Engl J Med 2021; 
384: 1885–98.
10 Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 
Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N Engl J Med 2021; 
published online May 5. https://doi.org/10.1056/NEJMc2104974.
11 Kustin T, Harel N, Finkel U, et al. Evidence for increased breakthrough rates of 
SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals. 
medRxiv 2021; published online April 16. 
https://doi.org/10.1101/2021.04.06.21254882 (preprint).
12 Kemp SA, Collier DA, Datir RP, et al. SARS-CoV-2 evolution during treatment 
of chronic infection. Nature 2021; 592: 277–82.
13 Di Genova C, Sampson A, Scott S, et al. Production, titration, neutralisation 
and storage of SARS-CoV-2 lentiviral pseudotypes. Figshare 2020; published 
online Dec 30. https://doi.org/10.6084/m9.figshare.13502580.v2 
(preprint).
